Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes in older adults.

    ... from curative treatment. Developments using the drugs lenalidomide , decitabine , and azacitidine have offered ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Current and future management options for myelodysplastic syndromes.

    ... and (ii) the emergence of US FDA-approved agents such as lenalidomide , azacitidine and decitabine . Prior to these ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. An update on the treatment of myelodysplastic syndromes.

    ... MDS, the novel antitumor immunomodulatory agent lenalidomide is approved for patients with del(5q), and two different ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

    ... gene expression profile may predict response to lenalidomide in patients who lack the deletion of 5q31.1. Tools such as ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Myelodysplastic syndromes.

    ... diagnosis is 72 and the median survival is 2.5 years. Lenalidomide , azacitidine , and decitabine are all ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Treatment of myelodysplastic syndromes in elderly patients.

    ... is essential. Likewise, immunomodulatory drugs, such as lenalidomide , can reduce transfusion requirements and reverse cytologic ...

    Research Article last updated 02/10/2012 - 9:43am.

  7. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 02/04/2014 - 1:37pm.

  8. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 07/31/2012 - 2:02pm.

  9. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 10/11/2011 - 5:58pm.